drugset / Trial / NCT06081582
Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single center phase II clinical study with a planned enrollment of 33 patients. The main objective is to evaluate the efficacy and safety of the PD-1 inhibitor toripalimab combined with cetuximab, cisplatin, and 5-FU regimen in the treatment of locally advanced oral squamous cell carcinoma patients who are initially unresectable.
Timeline
- Start
- 2023-07-06
- Primary completion
- 2024-03
- Completion
- 2024-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | — |
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | — |
| Subject | fluorouracil | Small molecule | 1000 mg/m2 | — |